Comparing the current results to its competitors, Disc Medicine Inc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.41 %, recorded in the same quarter.
Disc Medicine Inc , slower than the average decrease reported by the company's competitors of -28.23 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -28.23 %
November 5, 2024
Emerging Innovations in Hematologic Disease Treatment: A Spotlight on Disc Medicine Disc Medicine, Inc. a clinical-stage biopharmaceutical company operating in the niche of hematologic diseases, is making significant strides in both research and clinical development. As they prepare for their presentations at the 66th American Society of Hematology (ASH) Annual Meeting scheduled for December 7-10, 2024, the latest updates regarding their products and clinical trials shed light on their commitment to tackling these serious conditions. This article synthesizes recent key developments, presentations, and results from Disc Medicine, providing insight into the company’s strategic trajectory and market impact....
February 20, 2024
Following the recent announcement by Disc Medicine, Inc. (NASDAQ:IRON), a leading clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for patients afflicted with serious hematologic diseases, we explore the significance of the United States Food and Drug Administration (FDA) granting Fast Track Designation to DISC-0974, a potential breakthrough therapy for patients suffering from non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia.In a medical landscape where innovative treatments are constantly sought after, the Fast Track Designation by the FDA represents a major milestone for Disc Medicine and highlights the tremendous poten...
Sources:
Disc Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Disc Medicine Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
